Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene

详细信息    查看全文

• 作者：Trevor J. Powles (1) trevorpowles@aol.com
  Susan J. Diem (2)
  Carol J. Fabian (3)
  Patrick Neven (4)
  D. Lawrence Wickerham (5)
  David A. Cox (6)
  David Muram (6)
  Donato Agnusdei (6)
  Sherie A. Dowsett (6)
  Messan Amewou-Atisso (6)
  Steven R. Cummings (7)
• 关键词：Arzoxifene – ; Selective estrogen receptor modulator (SERM) – ; Breast cancer prevention – ; Clinical trial
• 刊名：Breast Cancer Research and Treatment
• 出版年：2012
• 出版时间：July 2012
• 年：2012
• 卷：134
• 期：1
• 页码：299-306
• 全文大小：508.3 KB
• 参考文献：1. Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388
  2. Veronesi U, Maisonneuve P, Costa A et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352:93–97
  3. Powles T, Eeles R, Ashley S et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98–101
  4. Cuzick J, Forbes J, Edwards R et al (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817–824
  5. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–645
  6. Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. [see comment] [erratum appears in JAMA 1999;282(22):2124]. JAMA 281:2189–2197
  7. Martino S, Costantino J, McNabb M et al (2004) The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials. Oncologist 9:116–125
  8. Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 295:2727–2741
  9. Cummings SR, Ensrud K, Delmas PD et al (2010) Lasofoxifene for postmenopausal women with osteoporosis. N Engl J Med 362:686–696
  10. La Croix A, Powles TJ, Osborn CK et al (2010) Breast cancer incidence in the PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 102:1706–1715
  11. Silverman SL, Christiansen C, Genant HK et al (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923–1934
  12. Archer DF, Pinkerton JV, Utian WH et al (2009) Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 16:1109–1115
  13. Suh N, Glasebrook AL, Palkowitz AD et al (2001) Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res 61:8412–8415
  14. Palkowitz AD, Glasebrook AL, Thrasher KJ, Hauser KL et al (1998) Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]benzothiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem 40:1407–1416
  15. Sato M, Turner CH, Wang T, Adrian MD et al (1998) LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 287:1–7
  16. Buzdar A, O’Shaughnessy JA, Booser DJ et al (2003) Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 21:1007–1014
  17. Baselga J, Llombart-Cussac A, Bellet M et al (2003) Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann Oncol 14:1383–1390
  18. Deshmane V, Krishnamurthy S, Melemed AS, Peterson P, Buzdar AU (2007) Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol 25:4967–4973
  19. Fabian CJ, Kimler BF, Anderson J et al (2004) Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res 10:5403–5417
  20. Cummings SR, McClung M, Reginster JY et al (2011) Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res 26:397–404
  21. Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886
  22. Cuzick J, Powles T, Veronesi U et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300
  23. Vogel VG, Costantino JP, Wickerham DL et al (2010) Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res 3:696–706
  24. Cuzick J, Forbes JF, Sestak I et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer–96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272–282
  25. Powles TJ, Ashley S, Tidy A et al (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283–290
• 作者单位：1. Breast Unit, The Cancer Centre London at Parkside, Wimbledon, London, UK2. University of Minnesota, Minneapolis, MN, USA3. Department of Internal Medicine, Division Hematology and Oncology, University of Kansas Medical Center, Kansas City, KS, USA4. Multidisciplinary Breast Center, University Hospitals Leuven, Leuven, Belgium5. National Surgical Adjuvant Breast and Bowel Project, Operations Center, Pittsburgh, PA, USA6. Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA7. San Francisco Coordinating Center, California Pacific Medical Center Research Institute, University of California, San Francisco, CA, USA
• ISSN：1573-7217

文摘

The Generations trial, a multicenter, placebo-controlled, double-blind trial, compared arzoxifene 20 mg/day and placebo in 9,354 postmenopausal women with osteoporosis (N = 5,252) or low bone mass (N = 4,102). Primary outcomes were vertebral fracture in the osteoporotic population and invasive breast cancer in all study participants. Here, we report the detailed breast cancer findings from the trial. Breast cancers were detected by annual mammograms and clinical examination. After 48 months follow-up, breast cancer incidence was compared between treatment groups by estrogen receptor (ER) and progesterone receptor (PR) status and baseline risk factors. Baseline breast cancer risk factors, including age, estimated Gail risk, and bone mineral density, were well balanced between treatment groups. A total of 75 breast cancers occurred 53 in the placebo group and 22 in the arzoxifene group (HR 0.41, 95 % CI 0.25–0.68, P < 0.001). There were 62 invasive breast cancers, 39 identified as invasive ER-positive (placebo 30, arzoxifene 9; HR 0.30, 95 % CI 0.14–0.63, P = 0.001) and 30 identified as invasive PR-positive (placebo 23, arzoxifene 7; HR 0.30, 95 % CI 0.13–0.71, P = 0.003). Breast cancer risk reduction with arzoxifene was similar between Gail risk groups (P interaction = 0.31) and between low bone mass and osteoporosis groups (P interaction = 0.35). Although generally well tolerated, there was a significant increase in venous thromboembolism, vasomotor symptoms, muscle cramps, and some gynecological events with arzoxifene. These findings demonstrate that in this study arzoxifene reduced the risk of ER-positive breast cancer in this population of postmenopausal women with low bone mass or osteoporosis, an effect similar to that seen with other SERMs.